The choice depends on whether you are studying SLCO1A2 (OATP1A2)'s role in drug uptake at the blood-brain barrier and intestine or its contributions to drug pharmacokinetics. The Knockout line is the standard tool for asking whether SLCO1A2 is required for cellular uptake of its substrates — including thyroid hormones, BSP, and many drugs subject to OATP1A2-mediated transport. Overexpression is useful for transport kinetics studies and inhibitor specificity testing. For pharmacokinetics research, the EDITGENE SLCO1A2 Knockout in Huh-7 provides a hepatocyte-derived background for studying transport biology, though SLCO1A2's principal physiological sites are intestine and brain endothelium rather than liver. The model is particularly useful for drug-drug interaction studies and OATP1A2 inhibitor characterization. Rescue with wild-type or transport-deficient SLCO1A2 enables mechanism and selectivity studies.

Yes. SLCO1A2 rescue experiments require attention to transporter topology: • Construct design: use a codon-modified SLCO1A2 sequence with a small C-terminal tag (FLAG, HA). SLCO1A2 has the canonical OATP 12-transmembrane architecture. • Surface expression validation: confirm plasma membrane localization before transport assays. • Polymorphism rescue: clinically relevant SLCO1A2 variants (e.g., R168C) can be introduced for pharmacogenomic studies in a controlled background. • Functional readout: rescue should restore cellular uptake of canonical OATP1A2 substrates (BSP, T3/T4, methotrexate) measured by appropriate detection methods. Huh-7 transduces efficiently with lentivirus and supports stable rescue line generation.